Show simple item record

Immunoscintigraphy with 99mTc labelled F(ab')2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanoma.

dc.contributor.authorCerny, T
dc.contributor.authorOwens, Susan E
dc.contributor.authorMackenzie, S A
dc.contributor.authorNuttall, Pamela M
dc.contributor.authorGosh, Anna K
dc.contributor.authorSmith, David B
dc.contributor.authorThatcher, Nick
dc.date.accessioned2010-07-21T16:12:24Z
dc.date.available2010-07-21T16:12:24Z
dc.date.issued1987
dc.identifier.citationImmunoscintigraphy with 99mTc labelled F(ab')2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanoma. 1987, 13 (3):130-3 Eur J Nucl Meden
dc.identifier.issn0340-6997
dc.identifier.pmid3622556
dc.identifier.urihttp://hdl.handle.net/10541/108116
dc.description.abstractImmunoscintigraphy was performed in 25 patients with malignant melanoma using a 99mTc labelled monoclonal antibody (225.28S). In four cases, imaging was repeated following treatment with recombinant gamma interferon. In 11 cases, tissue samples of metastatic lesions were investigated for the expression of melanoma associated antigens by immunohistochemical techniques. Overall, 59% of known lesions were detected by imaging. The highest rates of detection were in bone, liver and lymph nodes and the lowest in lung, stomach and bowel. Six lesions were detected which had not shown up on routine clinical and radiological examination. There was no evidence of enhanced or induced HMW-MAA expression following interferon treatment. This technique has been found to be useful in staging patients and has been free from side effects.
dc.language.isoenen
dc.subjectCancer Antigensen
dc.subjectCancer Metastasisen
dc.subjectCancer Proteinsen
dc.subjectSkin Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntibody Specificity
dc.subject.meshAntigens, Neoplasm
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshImmunoglobulin Fab Fragments
dc.subject.meshMale
dc.subject.meshMelanoma
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Metastasis
dc.subject.meshNeoplasm Proteins
dc.subject.meshSkin Neoplasms
dc.titleImmunoscintigraphy with 99mTc labelled F(ab')2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanoma.en
dc.typeArticleen
dc.identifier.journalEuropean Journal of Nuclear Medicineen
html.description.abstractImmunoscintigraphy was performed in 25 patients with malignant melanoma using a 99mTc labelled monoclonal antibody (225.28S). In four cases, imaging was repeated following treatment with recombinant gamma interferon. In 11 cases, tissue samples of metastatic lesions were investigated for the expression of melanoma associated antigens by immunohistochemical techniques. Overall, 59% of known lesions were detected by imaging. The highest rates of detection were in bone, liver and lymph nodes and the lowest in lung, stomach and bowel. Six lesions were detected which had not shown up on routine clinical and radiological examination. There was no evidence of enhanced or induced HMW-MAA expression following interferon treatment. This technique has been found to be useful in staging patients and has been free from side effects.


This item appears in the following Collection(s)

Show simple item record